The novel p53 isoform "delta p53" is a misfolded protein and does not bind the p21 promoter site

被引:7
|
作者
Garcia-Alai, Maria M. [1 ]
Tidow, Henning [1 ]
Natan, Eviatar [1 ]
Townsley, Fiona M. [1 ]
Veprintsev, Dmitry B. [1 ]
Fersht, Alan R. [1 ]
机构
[1] MRC, Ctr Prot Engn, Cambridge CB2 0QH, England
基金
英国医学研究理事会;
关键词
protein structure/folding; structure/function studies; DNA-binding domains; dominant-negative mutation;
D O I
10.1110/ps.036996.108
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The tumor suppressor p53 can be expressed as different isoforms because of promoter selection and mRNA editing. One isoform, "delta p53'' (Delta p53), results from what would be an unusual alternative splicing of exons 7/8 of the p53 gene, conserving the reading frame and generating a novel protein with proposed transcriptional activity essential for the intra S-phase checkpoint. Here, we show that the deletion of the 66 residues that correspond to strand beta 10 and the C-terminal helix of the core domain and the interconnecting linker to the tetramerization domain occurring in the Delta p53 isoform leads to a misfolded and unstable protein, prone to form soluble aggregates, which does not bind the p21 promoter site. The complex of coexpressed Delta p53 and flp53 is soluble in vitro and binds poorly to DNA. Our results provide a structural explanation for the dominant-negative effect of Delta p53 and its lack of transcriptional activity.
引用
收藏
页码:1671 / 1678
页数:8
相关论文
共 50 条
  • [41] p21 and p53 expression in oral precancerous lesion.
    Yamamoto, S
    Kawasaki, G
    Mazuno, A
    JOURNAL OF DENTAL RESEARCH, 2000, 79 : 398 - 398
  • [42] Prognostic and predictive value of p53 and p21 in breast cancer
    Elledge, RM
    Allred, DC
    BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) : 79 - 98
  • [43] The expression of p53 and p21 in giant cell arteritis.
    Nordborg, E
    Nordborg, C
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S387 - S387
  • [44] Expression of p53 and p21 in bladder carcinoma of Iraqi patients
    Al Chalabi, Rawaa
    Salih, Shahlaa M.
    Saad, Sajid
    Jawad, Hayder
    JOURNAL OF BIOLOGICAL RESEARCH-BOLLETTINO DELLA SOCIETA ITALIANA DI BIOLOGIA SPERIMENTALE, 2019, 92 (01): : 34 - 38
  • [45] ABSENCE OF MUTATION IN P21 IN BREAST CANCERS WITH WILDTYPE P53
    EVANS, AA
    PRIMROSE, JN
    ROYLE, GT
    CROOK, TR
    BRITISH JOURNAL OF SURGERY, 1995, 82 (11) : 1572 - 1573
  • [46] Overexpression of p53 protein and p53 mutations in oral carcinoma
    Barten, M
    Ostwald, C
    Gogacz, P
    Wukasch, Y
    Gundlach, K
    MildeLangosch, K
    Loning, T
    HEAD AND NECK CANCER - ADVANCES IN BASIC RESEARCH, 1996, 1114 : 313 - 319
  • [47] The p53/miRNAs/Ccna2 pathway serves as a novel regulator of cellular senescence: Complement of the canonical p53/p21 pathway
    Xu, Shun
    Wu, Weijia
    Huang, Haijiao
    Huang, Ruxiao
    Xie, Luoyijun
    Su, Ailing
    Liu, Shuang
    Zheng, Ruinian
    Yuan, Yuan
    Zheng, Hui-ling
    Sun, Xuerong
    Xiong, Xing-dong
    Liu, Xinguang
    AGING CELL, 2019, 18 (03)
  • [48] p53 gene mutations and p21 protein expression induced independently of p53, by TGF-β and γ-rays in squamous cell carcinoma cells
    Yoneda, K
    Yokoyama, T
    Yamamoto, T
    Hatabe, T
    Osaki, T
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (02) : 278 - 283
  • [49] Does p53 expression correlate with p21 expression in cancer of the uterine corpus? Reply
    Skomedal, H
    JOURNAL OF PATHOLOGY, 2000, 191 (03): : 341 - 342
  • [50] Multi-site phosphorylation of p53 by protein kinases inducible by p53 and DNA damage
    Meek, DW
    Campbell, LE
    Jardine, LJ
    Knippschild, U
    McKendrick, L
    Milne, DM
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) : 416 - 419